CAR T cell News and Research

RSS

The critical role of flow cytometry in CAR+ T-Cell trials

In this interview, Ryan Muise talks to AZoNetwork about the added value of using flow cytometry in CAR T-Cell clinical trials.

From Cerba Research 6 Dec 2022

Miracles Start in the Lab: the quest to find a vaccine to cure AIDS

To commemorate World AIDS Day, News Medical spoke to Dr. Larry Corey, an internationally renowned expert in virology, immunology, and vaccine development, and the former president and director of Fred Hutch, about his work within the field of HIV/AIDS research and vaccine development.

30 Nov 2022

CAR T-cell therapy in colorectal cancer

Researchers assessed the efficacy of CAR T-cells in the immunotherapy of colorectal cancer.

21 Nov 2022

Study finds no differences in CAR T-cell therapy outcomes among pediatric ALL patients across different socioeconomic levels

Social determinants of health affect the outcomes of many illnesses, and pediatric cancer is no exception. In fact, children with acute lymphoblastic leukemia (ALL) living in poverty are significantly more likely to relapse and die from their disease than those from wealthier backgrounds.

11 Nov 2022

Researchers use CRISPR-edited T cells to treat seriously ill children with resistant leukaemia

Researchers at Great Ormond Street Hospital for Children (GOSH) and UCL Great Ormond Street Institute of Child Health (UCL GOS ICH) have used CRISPR/Cas9 technology to engineer donor T cells to try to treat seriously ill children with resistant leukaemia, who had otherwise exhausted all available therapies.

27 Oct 2022

Researchers streamline way to manufacture CAR T-cells in just 24 hours

Researchers at University Hospitals (UH) Seidman Cancer Center and a biotech start-up company have developed a streamlined way to manufacture CAR T-cells for immunotherapy treatment in just 24 hours – an improvement over the team's previous benchmark of eight days and commercial suppliers that typically take three weeks.

25 Oct 2022

CAR T-cell therapy produces impressive results in first clinical trial in patients with multiple myeloma

A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan Kettering Cancer Center (MSK), Dana-Farber Cancer Institute and Roswell Park Comprehensive Cancer Center report in a new study published today by the New England Journal of Medicine.

29 Sep 2022

Study shows encouraging therapeutic options for patients with relapsed multiple myeloma

Mount Sinai researchers have published results that show encouraging therapeutic options for patients with the blood cancer multiple myeloma after first-line treatment with bispecific antibodies fails.

1 Sep 2022

Immune cells beyond CAR-T cells affect the durability of response to BCMA CAR T therapy in myeloma

Patients with myeloma whose tumor immune microenvironments had a more diverse baseline T-cell repertoire, fewer markers of immune cell exhaustion, and distinct changes to immune cell populations were more likely to have longer progression-free survival (PFS) after treatment with BCMA-targeted T-cell therapy.

30 Aug 2022

Oncolytic viruses boost the immune capacity to effectively target and destroy cancer cells

The immune system has evolved to safeguard the body from a wildly diverse range of potential threats. Among these are bacterial diseases, including plague, cholera, diphtheria and Lyme disease, and viral contagions such as influenza, Ebola virus and SARS CoV-2.

29 Aug 2022

OICR funding to help five research projects take the next step toward advancing cancer care

Five Ontario-based research projects will take the next step toward advancing cancer care in the province thanks to funding from the Ontario Institute for Cancer Research (OICR).

11 Aug 2022

Higher doses of CAR-T therapy achieve better survival rates for young patients with hard-to-treat B-ALL

Young people who received doses of tisagenlecleucel, a chimeric antigen receptor T cell (CAR-T) therapy, at the higher end of the FDA-approved dosing range had significantly better survival rates at one year compared with those who received lower doses within this range, according to research published today in Blood Advances.

8 Aug 2022

Preclinical study unlocks the promise of CAR T-cell therapy for treatment of solid tumors

Scientists at St. Jude Children's Research Hospital identified a molecular mechanism that in a preclinical study unlocked the promise of CAR T–cell therapy for treatment of solid tumors.

22 Jun 2022

New screening tool could increase the number of tests on solid tumor sample by up to 50 times

A screening tool developed at the University of Strathclyde, UK, could increase the number of tests on a solid tumor sample by up to 50 times.

21 Jun 2022

Creating CAR T cells without an immune brake

T cells are usually very good at eliminating diseased cells. But they seem to fail when it comes to tumor cells.

10 Jun 2022

Intestinal microbiome may contribute to the pathogenesis of MSI colon cancers, study suggests

Investigators from Rutgers Cancer Institute of New Jersey, New Jersey's only National Cancer Institute- Designated Comprehensive Cancer Center, led a collaborative study to examine the patterns of druggable oncogenic fusions in colon cancer specimens including microsatellite-stable and unstable (MSI) tumors.

19 May 2022

Novel method could bring life-saving benefits of CAR T-cell therapy to patients with acute myeloid leukemia

Massachusetts General Hospital researchers have developed a novel treatment strategy that has the potential to bring the life-saving benefits of chimeric antigen receptor T-cell therapy (CAR T) to patients with acute myeloid leukemia (AML) the most common form of leukemia in adults.

28 Apr 2022

Roswell Park experts to share latest advances in the treatment of blood-related cancers

Roswell Park Comprehensive Cancer Center specialists will share the latest advances and developments in the treatment of blood-related cancers at the 2022 Tandem Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR) in Salt Lake City, Utah, from April 23 to 26.

26 Apr 2022

CAR T-Cell Therapy: The Future of Cancer and HIV Treatment?

In this interview, News-Medical speaks to Professor Jun Huang about CAR T-cell therapy and its future as a potential treatment for cancer or HIV.

20 Apr 2022

Researchers identify certain gene regulation signatures in CAR T-resistant leukemia patients

Acute lymphoblastic leukemia (ALL) cells from patients whose cancers did not respond to CD19-targeted CAR T therapy had gene regulation signatures that could potentially facilitate treatment resistance, according to results presented at the AACR Annual Meeting 2022, held April 8-13.

13 Apr 2022